Bimekizumab治疗斑块型银屑病的研究进展
Research Progress of the Treatment of Plaque Psoriasis with Bimekizumab
DOI: 10.12677/acm.2024.1451697, PDF,   
作者: 张 昕, 常 伟, 谭 献, 郭佳敏, 陈 昭：华北理工大学附属工人医院，河北 唐山
关键词: 银屑病；Bimekizumab；IL-17A/IL-17F双重抑制；Psoriasis； Bimekizumab； IL-17A/IL-17F Dual Inhibition
摘要: 银屑病是一种慢性、难治性、炎症性皮肤病，发病率高，对银屑病患者及社会造成沉重的负担。随着医学研究的不断进步，针对特定作用机制的生物制剂以其治疗效果明显、不良反应较少而广泛应用于临床。研究显示，Bimekizumab可双重抑制IL-17A/IL-17F，被美国食品和药物管理局(FDA)批准用于中重度银屑病的成年患者，并且是第一个且目前为止唯一批准的用于选择性抑制两种主要细胞因子的药物，其治疗效果相较于单一抑制IL-17A更显著。因此，本文综述了Bimekizumab的作用机制、在银屑病中的研究进展，为银屑病的发病与治疗提供新思路。
Abstract: Psoriasis is a chronic, refractory, inflammatory skin disease, with a high incidence of incidence rate, which causes a heavy burden on patients with psoriasis and society. With the continuous progress of medical research, biological agents targeting specific mechanisms of action are widely used in clinical practice due to their significant therapeutic effects and fewer adverse reactions. Research has shown that Bimekizumab can double inhibit IL-17A/IL-17F, and is approved by the US Food and Drug Administration (FDA) for use in adult patients with moderate to severe psoriasis. It is the first and only approved to selectively inhibit two major cytokines, and its therapeutic effect is more significant than single inhibition of IL-17A. Therefore, this article reviews the mechanism of action and research progress of Bimekizumab in psoriasis, providing new ideas for the pathogenesis and treatment of psoriasis.
文章引用：张昕, 常伟, 谭献, 郭佳敏, 陈昭. Bimekizumab治疗斑块型银屑病的研究进展[J]. 临床医学进展, 2024, 14(5): 2384-2389. https://doi.org/10.12677/acm.2024.1451697

参考文献

[1] Takeshita, J., Grewal, S., Langan, S.M., et al. (2017) Psoriasis and Comorbid Diseases: Epidemiology. Journal of the American Academy of Dermatology, 76, 377-390. [Google Scholar] [CrossRef] [PubMed]
[2] Bu, J., Ding, R., Zhou, L., Chen, X. and Shen, E. (2022) Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Frontiers in Immunology, 13, Article 880201. [Google Scholar] [CrossRef] [PubMed]
[3] Conrad, C. and Gilliet, M. (2018) Psoriasis: From Pathogenesis to Targeted Therapies. Clinical Reviews in Allergy & Immunology, 54, 102-113. [Google Scholar] [CrossRef] [PubMed]
[4] Johansen, C., Usher, P.A., Kjellerup, R.B., Lundsgaard, D., Iversen, L. and Kragballe, K. (2009) Characterization of the Interleukin-17 Isoforms and Receptors in Lesional Psoriatic Skin. British Journal of Dermatology, 160, 319-324. [Google Scholar] [CrossRef] [PubMed]
[5] Blauvelt, A. and Chiricozzi, A. (2018) The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clinical Reviews in Allergy & Immunology, 55, 379-390. [Google Scholar] [CrossRef] [PubMed]
[6] Chang, S.H. and Dong, C. (2007) A Novel Heterodimeric Cytokine Consisting of IL-17 and IL-17F Regulates Inflammatory Responses. Cell Research, 17, 435-440. [Google Scholar] [CrossRef] [PubMed]
[7] Bertelsen, T., Iversen, L. and Johansen, C. (2018) The Human IL-17A/F Heterodimer Regulates Psoriasis-Associated Genes through IκBζ. Experimental Dermatology, 27, 1048-1052. [Google Scholar] [CrossRef] [PubMed]
[8] McGeachy, M.J., Cua, D.J. and Gaffen, S.L. (2019) The IL-17 Family of Cytokines in Health and Disease. Immunity, 50, 892-906. [Google Scholar] [CrossRef] [PubMed]
[9] Keijsers, R.R., Joosten, I., van Erp, P.E., Koenen, H.J. and van de Kerkhof, P.C. (2014) Cellular Sources of IL-17 in Psoriasis: A Paradigm Shift? Experimental Dermatology, 23, 799-803. [Google Scholar] [CrossRef] [PubMed]
[10] Chiricozzi, A., De Simone, C., Fossati, B. and Peris, K. (2019) Emerging Treatment Options for the Treatment of Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis: Evaluating Bimekizumab and Its Therapeutic Potential. Psoriasis: Targets and Therapy, 9, 29-35. [Google Scholar] [CrossRef] 
[11] Mills, K.H.G. (2023) IL-17 and IL-17-Producing Cells in Protection versus Pathology. Nature Reviews Immunology, 23, 38-54. [Google Scholar] [CrossRef] [PubMed]
[12] Furue, M., Furue, K., Tsuji, G. and Nakahara, T. (2020) Interleukin-17A and Keratinocytes in Psoriasis. International Journal of Molecular Sciences, 21, Article 1275. [Google Scholar] [CrossRef] [PubMed]
[13] Lo, Y.H., Li, C.S., Chen, H.L., et al. (2021) Galectin-8 Is Upregulated in Keratinocytes by IL-17A and Promotes Proliferation by Regulating Mitosis in Psoriasis. Journal of Investigative Dermatology, 141, 503-511.E9. [Google Scholar] [CrossRef] [PubMed]
[14] Ekman, A.K., Bivik Eding, C., Rundquist, I. and Enerbäck, C. (2019) IL-17 and IL-22 Promote Keratinocyte Stemness in the Germinative Compartment in Psoriasis. Journal of Investigative Dermatology, 139, 1564-1573.E8. [Google Scholar] [CrossRef] [PubMed]
[15] Xu, X., Prens, E., Florencia, E., et al. (2021) Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation. Frontiers in Immunology, 12, Article 719562. [Google Scholar] [CrossRef] [PubMed]
[16] Liu, Y., Zhang, C., Li, B., et al. (2021) A Novel Role of IL-17A in Contributing to the Impaired Suppressive Function of Tregs in Psoriasis. Journal of Dermatological Science, 101, 84-92. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, X., Angkasekwinai, P., Dong, C. and Tang, H. (2011) Structure and Function of Interleukin-17 Family Cytokines. Protein & Cell, 2, 26-40. [Google Scholar] [CrossRef] [PubMed]
[18] Monin, L. and Gaffen, S.L. (2018) Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harbor Perspectives in Biology, 10, a028522. [Google Scholar] [CrossRef] [PubMed]
[19] Wright, J.F., Bennett, F., Li, B., et al. (2008) The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex. Journal of Immunology, 181, 2799-2805. [Google Scholar] [CrossRef] [PubMed]
[20] Maroof, A., Smallie, T., Archer, S., et al. (2017) Dual IL-17A and IL-17F Inhibition with Bimekizumab Provides Evidence for IL-17F Contribution to Immune-Mediated Inflammatory Skin Response. Journal of Investigative Dermatology, 137, S120. [Google Scholar] [CrossRef] 
[21] Glatt, S., Baeten, D., Baker, T., et al. (2018) Dual IL-17A and IL-17F Neutralisation by Bimekizumab in Psoriatic Arthritis: Evidence from Preclinical Experiments and a Randomised Placebo-Controlled Clinical Trial That IL-17F Contributes to Human Chronic Tissue Inflammation. Annals of the Rheumatic Diseases, 77, 523-532. [Google Scholar] [CrossRef] [PubMed]
[22] Maroof, A., Okoye, R., Smallie, T., et al. (2017) Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells. Annals of the Rheumatic Diseases, 76, Article 213. [Google Scholar] [CrossRef] 
[23] Maroof, A., Baeten, D., Archer, S., Griffiths, M. and Shaw, S. (2017) IL-17F Contributes to Human Chronic Inflammation in Synovial Tissue: Preclinical Evidence with Dual IL-17A and IL-17F Inhibition with Bimekizumab in Psoriatic Arthritis. Annals of the Rheumatic Diseases, 76, A13. [Google Scholar] [CrossRef] 
[24] Guilloteau, K., Paris, I., Pedretti, N., et al. (2010) Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1α, and TNF-α Recapitulates Some Features of Psoriasis. Journal of Immunology, 184, 5263-5270. [Google Scholar] [CrossRef] [PubMed]
[25] Christmann, C., Zenker, S., Martens, L., et al. (2021) Interleukin 17 Promotes Expression of Alarmins S100A8 and S100A9 during the Inflammatory Response of Keratinocytes. Frontiers in Immunology, 11, Article 599947. [Google Scholar] [CrossRef] [PubMed]
[26] Johnston, A., Fritz, Y., Dawes, S.M., et al. (2013) Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation. Journal of Immunology, 190, 2252-2262. [Google Scholar] [CrossRef] [PubMed]
[27] Chiricozzi, A., Suárez-Fariñas, M., Fuentes-Duculan, J., et al. (2016) Increased Expression of Interleukin-17 Pathway Genes in Nonlesional Skin of Moderate-to-Severe Psoriasis Vulgaris. British Journal of Dermatology, 174, 136-145. [Google Scholar] [CrossRef] [PubMed]
[28] Van Baarsen, L.G., Lebre, M.C., van der Coelen, D., et al. (2014) Heterogeneous Expression Pattern of Interleukin 17A (IL-17A), IL-17F and Their Receptors in Synovium of Rheumatoid Arthritis, Psoriatic Arthritis and Osteoarthritis: Possible Explanation for Nonresponse to Anti-IL-17 Therapy? Arthritis Research & Therapy, 16, Article No. 426. [Google Scholar] [CrossRef] [PubMed]
[29] Reich, K., Papp, K.A., Blauvelt, A., et al. (2021) Bimekizumab versus Ustekinumab for the Treatment of Moderate to Severe Plaque Psoriasis (BE VIVID): Efficacy and Safety from a 52-Week, Multicentre, Double-Blind, Active Comparator and Placebo Controlled Phase 3 Trial. The Lancet, 397, 487-498. [Google Scholar] [CrossRef] 
[30] Warren, R.B., Blauvelt, A., Bagel, J., et al. (2021) Bimekizumab versus Adalimumab in Plaque Psoriasis. The New England Journal of Medicine, 385, 130-141. [Google Scholar] [CrossRef] 
[31] Reich, K., Warren, R.B., Lebwohl, M., et al. (2021) Bimekizumab versus Secukinumab in Plaque Psoriasis. The New England Journal of Medicine, 385, 142-152. [Google Scholar] [CrossRef] 
[32] Kokolakis, G., Warren, R.B., Strober, B., et al. (2023) Bimekizumab Efficacy and Safety in Patients with Moderate-to-Severe Plaque Psoriasis Who Switched from Adalimumab, Ustekinumab or Secukinumab: Results from Phase III/IIIb Trials. British Journal of Dermatology, 188, 330-340. [Google Scholar] [CrossRef] [PubMed]

为你推荐